Oryzon Genomics has announced its intention to carry out a capital increase that could reach 125 million euros, according to the call for an extraordinary meeting of shareholders, sent this morning to the National Securities Market Commission (CNMV). The proposal triggered the collapse of the stock on the stock market, which lost around 4%, although in the worst moments it sank by more than 7%, and its capitalization remains just over 270 million euros. Oryzon explains that the issue price will be above 2.35 euros per share, when it is currently trading above 3 euros per share.
The main proposal that will be put to the vote of the shareholders is the approval of a capital increase through cash contributions and with the exclusion of the pre-emptive subscription right for the current shareholders. The power to set the date, issue price and final terms of such extension will be delegated to the board of directors. The company sent the relevant documentation to the CNMV on Monday. The meeting will be held in second call on 12 December 2025.
In addition to the capital increase, the meeting will address other key issues related to corporate governance and talent management, such as a new remuneration policy, which will present the directors’ remuneration policy, which will be in force for the years 2026, 2027 and 2028.
A long-term incentive plan for managers and key personnel, including the executive chairman, and fixed compensation in shares will also be approved. A long-term, equity-based fixed compensation plan will also be voted on, with the dual objectives of “promoting talent attraction” and “rewarding” the board’s independent directors.
Losses until September
Oryzon Genomics presented its results between January and September on November 7, when it announced losses of almost 1.3 million euros in the first nine months of the year, a figure 44.6% lower than the negative result of 2.27 million euros for the same period in 2024, as reported by the biopharmaceutical company on Friday. The group’s financial income amounted to 607,190 euros between January and September, a figure that multiplies that of the same period in 2024 by more than six.
Oryzon’s R&D investments increased by 23.2% compared to the third quarter of 2024, and R&D activities amounted to €8.2 million as of September, of which €7.5 million corresponded to development and €700,000 to research. At the end of the third quarter of 2025, the biopharmaceutical company’s cash and financial investments reached 34.4 million euros.
As of September 30, Oryzon had a net worth of 116.7 million, which represents a 25.9% increase compared to the third quarter of the previous year. “We have secured more than $60 million (52 million euros) in the first half of 2025, which represents a major turning point for Oryzon,” emphasized Dr. Carlos Buesa, the company’s CEO.
“These funds will allow us to advance our clinical programs with a renewed strategic focus on the central nervous system, particularly in our studies of BPD, schizophrenia and ASD,” he added.
